miR-424 acts as a tumor radiosensitizer by targeting aprataxin in cervical cancer

Area of Science:

• Oncology
• Molecular Biology
• Radiotherapy Research

Background:

• Dysregulated microRNAs (miRNAs) are implicated in tumor cell radioresistance.
• Cervical cancer often develops resistance to radiotherapy, necessitating novel therapeutic approaches.
• Understanding the role of specific miRNAs in radioresistance is crucial for improving treatment outcomes.

Purpose of the Study:

• To investigate the role of miR-424 in the radioresistance of cervical cancer cells.
• To explore the potential of miR-424 as a therapeutic target for overcoming radioresistance in cervical cancer.

Main Methods:

• Quantitative real-time PCR to measure miR-424 expression in radioresistant and radiosensitive cervical cancer cells and patient specimens.
• In vitro experiments involving ectopic miR-424 expression to assess its effects on DNA damage, apoptosis, and cell cycle.
• In vivo studies using a xenograft model to evaluate the radiosensitizing effect of miR-424 agomiR treatment.
• Bioinformatic analysis and luciferase reporter assays to identify and validate the direct target of miR-424.

Main Results:

• miR-424 expression was significantly decreased in radioresistant cervical cancer cells and patient samples.
• Ectopic expression of miR-424 enhanced radiation-induced DNA damage, apoptosis, and G2/M cell cycle arrest in radioresistant cells.
• miR-424 agomiR treatment sensitized radioresistant cervical cancer cells to radiation in a xenograft model.
• Aprataxin was identified as a direct target of miR-424, mediating its effect on radiosensitivity.

Conclusions:

• miR-424 functions as a radiosensitizing miRNA in cervical cancer.
• Restoration of miR-424 expression can overcome radioresistance in cervical cancer.
• Targeting miR-424 represents a promising novel therapeutic strategy for radioresistant cervical cancers.